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Seroprevalence; Sri LankaAbstract The immunization program in Sri Lanka consistently reaches >90% cover-
age with oral poliovirus vaccines (OPV), and no polio supplementary vaccination
campaigns have been conducted since 2003. We evaluated serological protection
against polioviruses in children. A cross-sectional community-based survey was per-
formed in three districts of Sri Lanka (Colombo, Badulla, and Killinochi). Randomly
selected children in four age groups (9–11 months, 3–4 years, 7–9 years, and
15 years) were tested for poliovirus neutralizing antibodies. All 400 enrolled children
completed the study. The proportion of seropositive children for poliovirus Type 1
and Type 2 was >95% for all age groups; for poliovirus Type 3 it was 95%, 90%, 77%,
and 75% in the respective age groups. The vaccination coverage in our sample based
on vaccination cards or parental recall was >90% in all age groups. Most Sri Lankan
children are serologically protected against polioviruses through routine
immunization only. This seroprevalence survey provided baseline data prior to the
anticipated addition of inactivated poliovirus vaccine (IPV) into the Sri Lankan immu-
nization program and the switch from trivalent OPV (tOPV) to bivalent OPV (bOPV).
ª 2015 Ministry of Health, Saudi Arabia. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
With polio eradication making rapid progress, only
three countries remain in 2014 which had never
eradicated wild poliovirus (Afghanistan, Nigeria,
S68 D. Gamage et al.and Pakistan) [1]. In this context, a high priority is
assigned to the preparations for the posteradication
era. The key policy changes described in the
Polio Eradication and Endgame Strategic Plan
2013–2018 [2] are global cessation of the Type 2
component of the oral poliovirus vaccine (OPV)
(meaning the switch from trivalent OPV [tOPV] to
bivalent OPV [bOPV]); and the global introduction
of at least one dose of inactivated poliovirus vaccine
(IPV) into every countrys routine immunization
schedule. The strategy will allow for cessation of
circulation and emergence of vaccine-derived
poliovirus Type 2 (VDPV 2) while the last endemic
foci of wild poliovirus are cleared [3].
The last case of poliomyelitis in Sri Lanka was
reported in 1993 [4]. The routine immunization
program in Sri Lanka is considered to be performing
well and includes five doses of OPV administered at
2, 4, and 6 months of age as a primary series fol-
lowed by revaccinations at 18 months and 5 years
of age. The vaccination coverage with the third
OPV dose has consistently exceeded 95% nation-
wide [5]. Supplementary immunization activities
have been conducted to address known population
immunity gaps from 1995 to 2003, and there has
been no polio vaccination campaign since 2003.
Sri Lanka plans to introduce one dose of IPV into
its routine immunization schedule in 2015.
Following the recommendation of the Strategic
Advisory Group of Experts, one dose of IPV will be
introduced into the routine immunization schedule
of all OPV-using countries in 2015; this IPV dose will
be co-administered with a dose of OPV after
14 weeks of age [6]. The switch from tOPV to
bOPV is planned for April 2016.
This study provides baseline data on seropreva-
lence of polio neutralizing antibodies in targeted
age groups in Sri Lanka in anticipation of the IPV
introduction and tOPV to bOPV switch.
2. Methods
We performed a cross-sectional community-based
survey in three districts of Sri Lanka: Colombo,
Badulla, and Killinochi. The study area purposefully
represented the lower socioeconomic strata of the
Sri Lankan society: in Colombo, children were
selected from urban slum areas; in Badulla children
of tea plantation workers were selected; and the
district of Killinochi is considered less developed
overall. Children in four age groups were selected:
9–11 months, 3–4 years, 7–9 years, and 15 years
of age. The age groups were selected to assess
serological protection achieved after primary
immunization series as well as after revaccinationswith OPV at 18 months and 5 years. The oldest age
group was selected to assess serological protection
in older children.
The participants were selected using simple ran-
dom sampling from field level health registers kept
with the Medical Officers of Health. Parents of eli-
gible children were approached during regular vis-
its of Public Health Midwives, consented, and
enrolled. On the same day, the participants were
transported to the nearest health center where a
1 mL blood sample was collected and a short ques-
tionnaire administered.
The blood specimens were allowed to clot. Sera
were separated and transported to Colombo,
where they were stored at 20 C until the ship-
ment to the Centers for Disease Control and
Prevention (CDC) in Atlanta, GA, USA. The sera
were tested for the presence of poliovirus neutral-
izing antibodies using standard neutralization
assays at the virological laboratory at the CDC
[7,8]. Seropositivity was defined as reciprocal
titers of poliovirus neutralizing antibodies P8.
The vaccination history of the enrolled children
was recorded from vaccination cards when avail-
able; otherwise the history was obtained through
parental recall.
A sample size of 100 children in each age group
(to a total of 400 children) was calculated
to be sufficient to detect, at the 95% confidence
level, a seroprevalence point estimate with a
precision of approximately ±5% assuming P90%
seroprevalence.
Ethical clearance was obtained by the Ethical
Committees of the Ministry of Health, Sri Lanka
and of the World Health Organization, Geneva,
Switzerland.
Statistical analysis was performed using EpiInfo
3.5.3., point estimates and 95% confidence inter-
vals were calculated for seroprevalence propor-
tions and for median titers. The Chi-square
uncorrected two-tailed p value was calculated to
assess statistically significant differences in base-
line characteristics between districts; we consid-
ered any p < 0.05 as an indicator of statistical
significance.
This study was approved by the Ethics Review
Committee of the Ministry of Health, Sri Lanka
and by the WHOs Ethics Review Committee in
Geneva.
3. Results
We enrolled 400 eligible children and 400/400
(100%) completed the study. We did not encounter
any dropout because enrollment and the blood
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blood samples were of sufficient quantity, sera
were obtained, and transportation to the CDC,
Atlanta was carried out under proper cold chain
conditions. All samples were analyzed for the pres-
ence of poliovirus neutralizing antibodies at the
CDC, Atlanta.
The female to male ratio in the sample was
1:1.3; there were more families living with an aver-
age monthly income of USD <75 in Killinochi than in
Badulla or Colombo; and the vaccination history
with OPV indicated >90% coverage in all areas and
for all age groups (Table 1).
There were no significant differences in the sero-
logical results between the three districts. The
seroprevalence to all three serotypes was >90% for
the 9–11 months and 3–4 years age groups. For
the 7–9 years and 15 years age groups, the propor-
tion of seropositive children for poliovirus Type 1Table 1 Baseline characteristics and serological results.
9–11 mo 3–4 y
Baseline characteristics
Enrolled 100 100
Colombo 37 34
Badulla 30 32
Killinochi 33 34
Sex (% female); n/N (%)
Colombo 20/37 (54%) 14/34 (41%)
Badulla 11/30 (37%) 15/32 (47%)
Killinochi 12/33 (36%) 15/34 (44%)
Fully vaccinated with OPV (%) according to age; n/N (%)
Colombo 37/37 (100%) 34/34 (100%)
Badulla 29/30 (97%) 32/32 (100%)
Killinochi 33/33 (100%) 34/34 (100%)
Average monthly income per household <$75 (%);n/N (%)
Colombo 0/37 (0%) 0/34 (0%)
Badulla 1/30 (3%) 0/32 (0%)
Killinochi 12/33 (36%) 6/34 (18%)
Serological results –
Poliovirus Type 1
% Positive (95% CI) 96 (90.1, 98.9) 99 (94.6, 100)
Median titer,
(95% CI)
P1448
(P1448, P1448)
724.1
(455, 1152)
Poliovirus Type 2
% Positive (95% CI) 98 (93, 99.8) 97 (91.5, 99.4)
Median titer,
(95% CI)
P1448
(P1448, P1448)
576
(408, 724)
Poliovirus Type 3
% Positive
(95% CI)
95
(88.7, 98.4)
90
(82.4, 95.1)
Median titer,
(95% CI)
910
(576, 1152)
113
(64, 227)
CI = confidence interval; OPV = oral poliovirus vaccine.and Type 2 remained >90%, however for serotype
3 it dropped to 77% for 7–9-year-olds and to 75%
in 15-year-olds (Table 1, Figs. 1 and 2). The median
titers of poliovirus neutralizing antibodies were
high for all three serotypes in the youngest
age groups, and decreased with increasing age
(Table 1, Figs. 1 and 2). No children were found to
be seronegative to all three poliovirus types, and
there were 7/400 (1.8%) children seronegative for
two of the three serotypes. There was no
statistically significant difference observed in the
vaccination history among seropositive versus
seronegative children; the seronegative children
in our survey received 100% OPV doses according
to their age. Further, there was no statistical differ-
ence observed in seroprevalence between children
from families living with an average monthly
income of <USD 75 and children from families living
with higher monthly income.7–9 y 15 y Total
100 100 400
33 33 137
33 34 129
34 33 134
13/33 (39%) 11/33 (33%) 58/137 (42%)
17/33 (52%) 15/33 (44%) 58/129 (45%)
14/41 (41%) 14/33 (42%) 55/134 (41%)
33/33 (100%) 33/33 (100%) 137/137 (100%)
33/33 (100%) 34/34 (100%) 128/129 (99%)
34/34 (100%) 30/33 (91%) 131/134 (98%)
1/33 (3%) 0/33 (0%) 1/137 (1%)
3/33 (9%) 2/34 (6%) 6/129 (5%)
0/34 (0%) 3/33 (9%) 21/134 (16%)
– – –
99 (94.6, 100) 97 (91.5, 99.4) 98 (95.6, 98.9)
325
(181, 455)
90.5
(56, 144)
455
(455, 724)
99 (94.6, 100) 100 (96.4,100) 99 (96.6, 99.4)
227
(144, 455)
113
(90, 181)
455
(362, 576)
77
(67.5, 84.8)
75
(65.3, 83.1)
84
(80.3, 87.7)
36
(18, 90)
28
(11, 45)
91
(72, 144)
Fig. 1 Seroprevalence in the selected age groups with a 95% confidence interval.
Fig. 2 Median reciprocal antibody titers in the selected age groups with a 95% confidence interval. PV1 = poliovirus
serotype 1; PV2 = poliovirus serotype 2; PV3 = poliovirus serotype 3.
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In our study we observed high serological protection
against polioviruses in all age groups and for all
three serotypes. The Sri Lankan immunization pro-
gram has achieved a high level of population immu-
nity through its routine immunization program and
without polio supplementary immunization activi-
ties. Our study purposefully selected areas with
higher proportions of children from lower socioeco-
nomic strata; we therefore hypothesize that sero-
prevalence in other populations of Sri Lanka would
likely be equal to or higher than our findings.
We observed declining seroprevalence of polio-
virus Type 3 neutralizing antibodies in the older
age groups while seroprevalence against poliovirusType 1 and Type 2 remained unchanged with age.
Further, as expected, the median titer of poliovirus
neutralizing antibodies declined for all three sero-
types with interval from the last vaccination, which
in this study, corresponds with increasing age
[9,10]. This decline, including decline to nonde-
tectable titers (i.e., <1:8) for some individuals, does
not imply loss of protection against paralytic disease,
as demonstrated by rapid anamnestic responses fol-
lowing revaccination in older adults [11,12].
However, because of rapidly waning mucosal immu-
nity, these individualswould likely excretepolioviruses
in stools and therefore participate in the chain of
transmission if exposed to live or VDPVs [13].
This study had some limitations. The selection of
participants was based on the knowledge of the
High seroprevalence against polioviruses in Sri Lanka S71area Public Health Midwife and available field level
registers kept with the Medical Officers of Health.
This may have meant that some households were
excluded from participation because they were
not included in the registers. However, the Sri
Lankan health system provides registration of all
births. In Sri Lanka, very few children are unregis-
tered with the Medical Officers and therefore we
believe that this bias was unimportant. Further,
the sample size calculation assumed seropreva-
lence level of P90%, however, for serotype 3,
the seroprevalence was lower and this resulted in
a slightly wider 95% confidence interval than origi-
nally anticipated.
Sri Lanka is well positioned to implement the
changes to its immunization program recom-
mended by the Strategic Advisory Group of
Experts of the WHO—the introduction of one dose
of IPV and the switch from tOPV to bOPV. Our
results provide important baseline data prior to
the switch; repeating a similar survey after the
switch will allow assessment of population immu-
nity to polioviruses achieved with the new polio
immunization schedule.
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